MYH6 sirna

MYH6 siRNA (Human)

Cat. Num. AAA829282

• Gene Names: MYH6; ASD3; MYHC; SSS3; CMH14; MYHCA; CMD1EE; alpha-MHC
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: MYH6; MYH6 siRNA (Human); MYHCA; Myosin-6; Myosin heavy chain 6; Myosin heavy chain. cardiac muscle alpha isoform; MyHC-alpha; MYH6 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: MYH6 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1939

• Applicable Applications for MYH6 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human MYH6 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for MYH6 sirna

siRNA to inhibit MYH6 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 156104908
• NCBI GeneID: 4624
• NCBI Accession #: NP_002462.2
• NCBI GenBank Nucleotide #: NM_002471.3
• UniProt Accession #: P13533; Q13943; Q14906; Q14907; A2RTX1; D9YZU2
• Molecular Weight: 223,735 Da
• NCBI Official Full Name: myosin-6
• NCBI Official Synonym Full Names: myosin, heavy chain 6, cardiac muscle, alpha
• NCBI Official Symbol: MYH6
• NCBI Official Synonym Symbols: ASD3; MYHC; SSS3; CMH14; MYHCA; CMD1EE; alpha-MHC
• NCBI Protein Information: myosin-6
• UniProt Protein Name: Myosin-6
• Protein Family: Myosin
• UniProt Gene Name: MYH6
• UniProt Synonym Gene Names: MYHCA; MyHC-alpha
• UniProt Entry Name: MYH6_HUMAN

NCBI Description

Cardiac muscle myosin is a hexamer consisting of two heavy chain subunits, two light chain subunits, and two regulatory subunits. This gene encodes the alpha heavy chain subunit of cardiac myosin. The gene is located ~4kb downstream of the gene encoding the beta heavy chain subunit of cardiac myosin. Mutations in this gene cause familial hypertrophic cardiomyopathy and atrial septal defect 3. [provided by RefSeq, Mar 2010]

Uniprot Description

MYH6: Muscle contraction. Defects in MYH6 are the cause of atrial septal defect type 3 (ASD3). ASD3 is a congenital heart malformation characterized by incomplete closure of the wall between the atria resulting in blood flow from the left to the right atria. Defects in MYH6 are the cause of familial hypertrophic cardiomyopathy type 14 (CMH14). It is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations,and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. Defects in MYH6 are the cause of cardiomyopathy dilated type 1EE (CMD1EE). It is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. Defects in MYH6 are the cause of susceptibility to sick sinus syndrome type 3 (SSS3). The term 'sick sinus syndrome' encompasses a variety of conditions caused by sinus node dysfunction. The most common clinical manifestations are syncope, presyncope, dizziness, and fatigue. Electrocardiogram typically shows sinus bradycardia, sinus arrest, and/or sinoatrial block. Episodes of atrial tachycardias coexisting with sinus bradycardia ('tachycardia-bradycardia syndrome') are also common in this disorder. SSS occurs most often in the elderly associated with underlying heart disease or previous cardiac surgery, but can also occur in the fetus, infant, or child without heart disease or other contributing factors. MYH6 variations are associated with susceptibility to sick sinus syndrome (PubMed:21378987). The lifetime risk of being diagnosed with sick sinus syndrome is higher for carriers of variant p.Arg721Trp than for non-carriers (PubMed:21378987).

Protein type: Motor; Motility/polarity/chemotaxis

Chromosomal Location of Human Ortholog: 14q12

Cellular Component: nucleoplasm; sarcomere; focal adhesion; myofibril; cytoplasm; stress fiber; muscle myosin complex; cytosol; myosin complex; Z disc

Molecular Function: calmodulin binding; microfilament motor activity; ATPase activity; actin-dependent ATPase activity; actin binding; protein kinase binding; ATP binding

Biological Process: adult heart development; striated muscle contraction; atrial cardiac muscle morphogenesis; metabolic process; in utero embryonic development; regulation of heart rate; Wnt receptor signaling pathway through beta-catenin; sarcomere organization; regulation of heart contraction; visceral muscle development; muscle filament sliding; BMP signaling pathway; regulation of ATPase activity; myofibril assembly; muscle contraction; cardiac muscle fiber development; regulation of blood pressure; ventricular cardiac muscle morphogenesis; regulation of the force of heart contraction

Disease: Sick Sinus Syndrome 3, Susceptibility To; Cardiomyopathy, Familial Hypertrophic, 14; Cardiomyopathy, Dilated, 1ee; Atrial Septal Defect 3; Cardiomyopathy, Familial Hypertrophic, 1